Rare Registry Updates

  • Posted: 2023-12-20
    Updated: 2023-12-20

    Tumor infiltrating lymphocyte (TIL) therapy, first pioneered by Dr. Stephen Rosenberg from the National Cancer Institute, isolates immune cells called lymphocytes from a patient’s surgically removed tumor that are then grown in large quantities in the lab. The army of grown TILs are then reinfused back into the patient where they recognize and destroy cancer cells in the body. On March 24th, 2023, Iovance submitted a Biologics License Application (BLA) to the FDA for the approval of Lifileucel. The FDA decision is expected by the end of February 2024.

  • Posted: 2023-11-16
    Updated: 2023-11-16

    RARE's SMR PosterThe Melanoma Research Alliance is excited to share a poster presentation called RARE: A Registry for Patients with Acral and Mucosal Melanoma which was presented last week at the Society for Melanoma Research (SMR)’s 20thannual Congress. SMR aims to enhance communication among melanoma researchers by organizing annual research congresses and works to emphasiz new research results to engage basic and clinical researchers. In addition, SMR works to promote collaboration among organizations focused on prevention, screening, and surveillance, facilitate partnerships among major research groups, and represent the melanoma research community to the public and funding agencies.

  • Posted: 2023-08-17
    Updated: 2023-08-23

    Join the RARE Registry team on August 23 at 12:30 pm ET to hear updates on data from the first 100 participants of RARE! During this special webinar, you’ll meet the RARE Registry staff and some of the RARE patient advisors, learn about some of the exciting data collected so far, and hear about new features available to RARE participants.  

  • Posted: 2022-09-22
    Updated: 2022-09-22

    Despite the tremendous progress in treating melanoma, approximately one third of patients don’t benefit from currently approved therapies. This includes the majority of people with rare forms of melanoma — melanomas that develop in the eye, nailbeds, palms, soles of the feet, and various mucosal membranes. Patients facing these subtypes tend not to respond as well to current treatments as patients with cutaneous melanomas that arise on sun-exposed skin. But as investigators continue to chip away at understanding what causes these melanomas and how they differ from UV-driven cutaneous melanomas, the hope is the better understanding they reap will be sown into improved treatments for these patients.